Immunotoxin therapy for hematologic malignancies: where are we heading?

被引：20
|
作者：
Madhumathi, Jayaprakasam [1 ]
Devilakshmi, Sithambaram [1 ]
Sridevi, Surapally [1 ]
Verma, Rama S. [1 ]
机构：
[1] Indian Inst Technol, Stem Cell & Mol Biol Lab, Bhupat & Jyoti Mehta Sch Biosci, Dept Biotechnol, Chennai 600036, Tamil Nadu, India
来源：
DRUG DISCOVERY TODAY | 2016年 / 21卷 / 02期
关键词：
ACUTE LYMPHOBLASTIC-LEUKEMIA; COLONY-STIMULATING FACTOR; ACUTE MYELOID-LEUKEMIA; HAIRY-CELL LEUKEMIA; MEDIATES POTENT APOPTOSIS; TARGETED CANCER-THERAPY; PHASE-I TRIAL; RECOMBINANT IMMUNOTOXIN; RFB4(DSFV)-PE38 BL22; SINGLE-CHAIN;
D O I：
10.1016/j.drudis.2015.05.002
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The identification of numerous unique targets in recent years has led to the development of various immunotoxins (ITs) for treating hematological malignancies. Some of these ITs have advanced to clinical trials and have resulted in a high response rate against leukemia. Newer targets with improve specificity are also being identified for targeting several leukemias. Currently, several modified versions of ITs with increased efficacy are being constructed and evaluated for cytotoxicity in vitro as well as in vivo. Here, we summarize recent advances in preclinical and clinical studies of recombinant ITs targeting diverse surface receptors.
引用
收藏
页码：325 / 332
页数：8
相关论文
共 50 条
  • [21] CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?
    Fischer, Luise
    Grieb, Nora
    Platzbecker, Uwe
    Vucinic, Vladan
    Merz, Maximilian
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, : 19 - 27
  • [22] Dual diagnosis: Where we are and where we are heading
    Levin, FR
    Evans, SM
    PSYCHIATRIC ANNALS, 2001, 31 (04) : 241 - 242
  • [23] Echocardiography: where are we now and where are we heading?
    Picard, MH
    WHAT'S NEW IN CARDIOVASCULAR IMAGING?, 1998, 204 : 323 - 331
  • [24] BioPAX in 2024: Where we are and where we are heading
    Beust, Cecile
    Becker, Emmanuelle
    Theret, Nathalie
    Dameron, Olivier
    COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2024, 23 : 3999 - 4010
  • [25] Direct annuloplasty: where are we at and where are we heading?
    Singh, Gagan D.
    Kiaii, Bob
    ANNALS OF CARDIOTHORACIC SURGERY, 2021, 10 (01) : 170 - 171
  • [26] Service developments: where we are and where we are heading for
    Pejovic Milovancevic, Milica
    Milavic, Gordana
    Lahuis, Bertine
    Anagnostopoulos, Dimitris
    EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2011, 20 (01) : S65 - S65
  • [27] Liver Transplantation: Where We Are and Where We Are Heading
    Esquivel, C. O.
    TRANSPLANTATION PROCEEDINGS, 2010, 42 (02) : 610 - 612
  • [28] Immunotoxin therapy of hematological malignancies
    Pasqualucci, L
    Flenghi, L
    Terenzi, A
    Bolognesi, A
    Stirpe, F
    Bigerna, B
    Falini, B
    HAEMATOLOGICA, 1995, 80 (06) : 546 - 554
  • [29] Research Integrity: Where We Are and Where We Are Heading
    Zhaksylyk, Alikhan
    Zimba, Olena
    Yessirkepov, Marlen
    Kocyigit, Burhan Fatih
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2023, 38 (47)
  • [30] Cell therapy for acute myocardial infarction: where are we heading?
    Kai C Wollert
    Helmut Drexler
    Nature Clinical Practice Cardiovascular Medicine, 2004, 1 : 61 - 61
12345